Antiemetic therapy for high-dose chemotherapy with transplantation

Report of a retrospective analysis of a 5-HT3 regimen and literature review

Edith A. Perez, Terry Tiemeier, Lawrence A. Solberg

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The goal of this work was to evaluate the efficacy of 5-HT3 receptor antagonist regimens in the transplant setting through a retrospective analysis of clinic patients and a review of the literature. A retrospective study was performed to evaluate the efficacy of an antiemetic regimen in 24 patients receiving high-dose chemotherapy with bone marrow transplantation. The antiemetic agent used in 96% of the patients was single-agent ondansetron 0.15 mg/kg as a continuous infusion every 12 h starting on the first day of chemotherapy. Efficacy or failure was defined by the need for administration of rescue antiemetics, as documented by nurses' notes and pharmacy records. Overall, 23 (96%) patients experienced antiemetic failure within the first 3 days. Rescue antiemetics yielded improved control of nausea and vomiting in 16 of 23 (70%) patients. These data demonstrate poor antiemetic efficacy of single-agent, continuous-infusion ondansetron in a small group of patients receiving high-dose chemotherapy with bone marrow transplantation. These data are considered in the context of a thorough literature review that shows the limitations of previously reported antiemetic studies in this setting, potential pharmacokinetic interactions, and also highlights the utilization of combination therapy, administered orally or intravenously, to improve efficacy and tolerability of antiemetic therapy. A number of recent investigations suggest that appropriate doses of 5-HT3 receptor antagonists with phenothiazine and corticosteroids can improve the safety and efficacy of antiemetic regimens in patients undergoing transplantation.

Original languageEnglish (US)
Pages (from-to)413-424
Number of pages12
JournalSupportive Care in Cancer
Volume7
Issue number6
DOIs
StatePublished - Nov 1999

Fingerprint

Antiemetics
Transplantation
Drug Therapy
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Ondansetron
Therapeutics
Bone Marrow Transplantation
Nausea
Vomiting
Adrenal Cortex Hormones
Retrospective Studies
Pharmacokinetics
Nurses
Transplants
Safety

Keywords

  • 5-HT receptor antagonists
  • Antiemetic
  • Bone marrow transplantation
  • High-dose chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Antiemetic therapy for high-dose chemotherapy with transplantation : Report of a retrospective analysis of a 5-HT3 regimen and literature review. / Perez, Edith A.; Tiemeier, Terry; Solberg, Lawrence A.

In: Supportive Care in Cancer, Vol. 7, No. 6, 11.1999, p. 413-424.

Research output: Contribution to journalArticle

@article{888794ac43ed407199406f546f1d6460,
title = "Antiemetic therapy for high-dose chemotherapy with transplantation: Report of a retrospective analysis of a 5-HT3 regimen and literature review",
abstract = "The goal of this work was to evaluate the efficacy of 5-HT3 receptor antagonist regimens in the transplant setting through a retrospective analysis of clinic patients and a review of the literature. A retrospective study was performed to evaluate the efficacy of an antiemetic regimen in 24 patients receiving high-dose chemotherapy with bone marrow transplantation. The antiemetic agent used in 96{\%} of the patients was single-agent ondansetron 0.15 mg/kg as a continuous infusion every 12 h starting on the first day of chemotherapy. Efficacy or failure was defined by the need for administration of rescue antiemetics, as documented by nurses' notes and pharmacy records. Overall, 23 (96{\%}) patients experienced antiemetic failure within the first 3 days. Rescue antiemetics yielded improved control of nausea and vomiting in 16 of 23 (70{\%}) patients. These data demonstrate poor antiemetic efficacy of single-agent, continuous-infusion ondansetron in a small group of patients receiving high-dose chemotherapy with bone marrow transplantation. These data are considered in the context of a thorough literature review that shows the limitations of previously reported antiemetic studies in this setting, potential pharmacokinetic interactions, and also highlights the utilization of combination therapy, administered orally or intravenously, to improve efficacy and tolerability of antiemetic therapy. A number of recent investigations suggest that appropriate doses of 5-HT3 receptor antagonists with phenothiazine and corticosteroids can improve the safety and efficacy of antiemetic regimens in patients undergoing transplantation.",
keywords = "5-HT receptor antagonists, Antiemetic, Bone marrow transplantation, High-dose chemotherapy",
author = "Perez, {Edith A.} and Terry Tiemeier and Solberg, {Lawrence A.}",
year = "1999",
month = "11",
doi = "10.1007/s005200050302",
language = "English (US)",
volume = "7",
pages = "413--424",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Antiemetic therapy for high-dose chemotherapy with transplantation

T2 - Report of a retrospective analysis of a 5-HT3 regimen and literature review

AU - Perez, Edith A.

AU - Tiemeier, Terry

AU - Solberg, Lawrence A.

PY - 1999/11

Y1 - 1999/11

N2 - The goal of this work was to evaluate the efficacy of 5-HT3 receptor antagonist regimens in the transplant setting through a retrospective analysis of clinic patients and a review of the literature. A retrospective study was performed to evaluate the efficacy of an antiemetic regimen in 24 patients receiving high-dose chemotherapy with bone marrow transplantation. The antiemetic agent used in 96% of the patients was single-agent ondansetron 0.15 mg/kg as a continuous infusion every 12 h starting on the first day of chemotherapy. Efficacy or failure was defined by the need for administration of rescue antiemetics, as documented by nurses' notes and pharmacy records. Overall, 23 (96%) patients experienced antiemetic failure within the first 3 days. Rescue antiemetics yielded improved control of nausea and vomiting in 16 of 23 (70%) patients. These data demonstrate poor antiemetic efficacy of single-agent, continuous-infusion ondansetron in a small group of patients receiving high-dose chemotherapy with bone marrow transplantation. These data are considered in the context of a thorough literature review that shows the limitations of previously reported antiemetic studies in this setting, potential pharmacokinetic interactions, and also highlights the utilization of combination therapy, administered orally or intravenously, to improve efficacy and tolerability of antiemetic therapy. A number of recent investigations suggest that appropriate doses of 5-HT3 receptor antagonists with phenothiazine and corticosteroids can improve the safety and efficacy of antiemetic regimens in patients undergoing transplantation.

AB - The goal of this work was to evaluate the efficacy of 5-HT3 receptor antagonist regimens in the transplant setting through a retrospective analysis of clinic patients and a review of the literature. A retrospective study was performed to evaluate the efficacy of an antiemetic regimen in 24 patients receiving high-dose chemotherapy with bone marrow transplantation. The antiemetic agent used in 96% of the patients was single-agent ondansetron 0.15 mg/kg as a continuous infusion every 12 h starting on the first day of chemotherapy. Efficacy or failure was defined by the need for administration of rescue antiemetics, as documented by nurses' notes and pharmacy records. Overall, 23 (96%) patients experienced antiemetic failure within the first 3 days. Rescue antiemetics yielded improved control of nausea and vomiting in 16 of 23 (70%) patients. These data demonstrate poor antiemetic efficacy of single-agent, continuous-infusion ondansetron in a small group of patients receiving high-dose chemotherapy with bone marrow transplantation. These data are considered in the context of a thorough literature review that shows the limitations of previously reported antiemetic studies in this setting, potential pharmacokinetic interactions, and also highlights the utilization of combination therapy, administered orally or intravenously, to improve efficacy and tolerability of antiemetic therapy. A number of recent investigations suggest that appropriate doses of 5-HT3 receptor antagonists with phenothiazine and corticosteroids can improve the safety and efficacy of antiemetic regimens in patients undergoing transplantation.

KW - 5-HT receptor antagonists

KW - Antiemetic

KW - Bone marrow transplantation

KW - High-dose chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032885080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032885080&partnerID=8YFLogxK

U2 - 10.1007/s005200050302

DO - 10.1007/s005200050302

M3 - Article

VL - 7

SP - 413

EP - 424

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 6

ER -